ATS 2020 Advance Program

Medicine. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of pulmonary medicine. Speakers and Talks to be Announced TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE A3 EARLY COPD: GETTING TO THE ROOT OF THE PROBLEM Assemblies on Clinical Problems; Environmental, Occupational and Population Health; Pulmonary Infections and Tuberculosis; Respiratory Cell and Molecular Biology; Respiratory Structure and Function 9:15 a.m. - 11:15 a.m. Target Audience Clinicians providing care to patients with obstructive disease, and translational investigators. Objectives At the conclusion of this session, the participant will be able to: • understand the burden of early COPD; • learn and understand the pathogenesis of early COPD; • utilize imaging characteristics to define this population and its long term outcome. Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder with varying presentations and progression, but limited disease-modifying therapies. “Early disease” should be distinguished from “late mild disease.” An operational definition of early COPD has been recently proposed: ever-smokers (=10 pack-years) younger than 50 years with any of these abnormalities: FEV1/FVClower limit of normal; compatible CT abnormalities; or FEV1 decline (=60 mL/year). To reduce COPD’s long-term societal impact, the goal of interventions must change, from solely focusing on reducing symptoms and exacerbations in advanced disease, to halting pathological progression in early disease. Chairing: J.A. Wedzicha, MD, PhD, ATSF, London, United Kingdom W. Zhang, MD, New York, NY J.L. Curtis, MD, ATSF, Ann Arbor, MI 9:15 Overview of and Definition of Early COPD F.J. Martinez, MD, MS, New York, NY 9:25 GOLD 0: Do Symptoms Predict the Development of COPD? J. Allinson, MD, PhD, London, United Kingdom 9:39 Contribution of Early life Exposures to the Development of COPD A. Agusti, MD, Barcelona, Spain 9:53 Role of Immune System Alterations C.M. Freeman, PhD, Ann Arbor, MI 10:07 Mucin Abnormalities in Early COPD M. Kesimer, PhD, MSci, Chapel Hill, NC 10:21 Can We Use Imaging to Identify Early COPD? M.K. Han, MD, MS, Ann Arbor, MI 10:35 Therapeutic Trials in Early COPD J.A. Wedzicha, MD, PhD, ATSF, London, United Kingdom 10:50 Where Do We Go from Here? B.R. Celli, MD, Boston, MA 11:05 Discussion F.J. Martinez, MD, MS, New York, NY CLINICAL • TRANSLATIONAL CRITICAL CARE TRACK A4 THE NEW ERA OF CRITICAL CARE FOR CANCER PATIENTS: CELLS TO SYSTEMS Assemblies on Critical Care; Clinical Problems; Thoracic Oncology 9:15 a.m. - 11:15 a.m. ATS 2020 • Philadelphia, PA SUNDAY • MAY 17 37